GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Mar 31, 2025

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001062822-25-000029General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

7979.32% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-3468.94% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

15.46% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

15.93% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

97.62% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-2034.79% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1212.60% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

241.13% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20266/8 normalizedLevel 3 Jun 30, 20266/8 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Decreased

Previous: -2979.17%
Current: -3468.94%
Delta: -489.77%

Inventory Pressure Increased

Previous: 3.85%
Current: 15.93%
Delta: 12.08%

Margin Increased

Previous: 89.73%
Current: 97.62%
Delta: 7.89%

Profitability Increased

Previous: -3284.74%
Current: -2034.79%
Delta: 1249.95%

R And D Intensity Decreased

Previous: 1407.77%
Current: 1212.60%
Delta: -195.17%

Sbc Intensity Increased

Previous: 224.95%
Current: 241.13%
Delta: 16.18%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CASH_GENERATION_DECREASED →Transitioned To · LXRX INVENTORY_PRESSURE_INCREASED →Transitioned To · LXRX MARGIN_INCREASED →Transitioned To · LXRX PROFITABILITY_INCREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.